Cell antigenic profile of Leptospira strains isolated in Leon and Chinandega, Nicaragua.

Authors

  • N Batista Instituto Finlay, Vicepresidencia de Investigaciones, (Ciudad Habana, Cuba)
  • DF Arencibia Instituto Finlay, Vicepresidencia de Investigaciones, (Ciudad Habana, Cuba)
  • LA Rosario Instituto de Farmacia y Alimentos (IFAL, U.H), (Ciudad de la Habana, Cuba.)
  • W Jirón Escuela de Veterinaria, Universidad Nacional Autónoma de Nicaragua (León, Nicaragua.)
  • Ch Duttman Escuela de Veterinaria, Universidad Nacional Autónoma de Nicaragua (León, Nicaragua.)

Keywords:

Leptospirosis, Vax-SPIRAL®, antigenic cellular profile, Nicaragua

Abstract

Objective.The following work was development with the objective of determining the profiles cellular antigenics that are recognized by the serum of people vaccinated with vax-SPIRAL® of obtained strains of the León and Chinandega departments.

Methods. Blood cultures samples were analyzed taken in sharp phase to cases with suspicion leptospirosis clinic, being determined the profiles antigenics by means of electrophoresis of whole cells and western blotting using as antibodies, serums coming from people vaccinated with vax-SPIRAL®.

Results and conclusions. A great antigenic homology was evidenced among all the studied strains. The present study results suggest that in León and Chinandega departments circulate L. interrogans strains with a strong antigenic recognition front of serums of people vaccinated with vax-SPIRAL®

Downloads

Download data is not yet available.

References

Cachay ER, Vinetz JM. A global research agenda for leptospirosis. Journ Postgrad Med. 2005; 51(3):174-178.

Boursaux C, Saint Girons I, Zuerner RL. Leptospira genomics. Electrophoresis. 1998; 19:589-592.

Silva EF, Medeiros MA, McBride AJ, Matsunaga J, Esteves GS, Ramos JG. The terminal portion of leptospiral immunoglobulin-like protein LigA confers protective immunity against lethal infection in the hamster model of leptospirosis. Vaccine. 2007; 25: 6277-6286.

Sandow K, Ramírez W. Leptospirosis. REDVET. 2005; 6(6):13-15.

González A, Rodríguez Y, Batista N, Valdés Y, Núñez JF, Mirabal M. Inmunogenicidad y capacidad protectora en hámsters de vacunas antileptospirósicas monovalentes de células enteras del serogrupo Ballum. Rev Argent Microbiol. 2005; 37:169-175.

Flecher W. Recent work on leptospirosis, tsutsugamushi disease and tropical typhus in the Federated Malay States. Trans Roy Soc Trop Med Hyg.1928; 21:265-282.

Laemmli NK. Cleavage of structural proteins during the assembly of the head of bacteriophage t4. Nature. 1970; 227: 680-685.

Burnnette WN. Western Blotting electrophoretic transfer of protein from sodium dodecyl suphate polyacrylamide gel to unmodified nitrocelulose and radiographic detection with antobodies and radioiodinated protein A. Anal Biochem. 1980; 112:192-200.

Levett PN. Leptospirosis. Clin Microbiol Rev. 2001; 14(2): 296-326.

Cullen PA, Cordwell SJ, Bulach DM, Haake DA, Adler B. Global analysis of outer membrane proteins from Leptospira interrogans serovar lai. Infect Immun. 2002; 770:2311-2318.

Guerreiro H, Croda J, Flannery B, Mazel M, Matsunaga J. Leptospiral proteins recognized during the humoral immune response to leptospirosis in humans. Infect Immun. 2001; 69(8):4958-4968.

Nally JE, Whitelegge JP, Aguilera R, Pereira MN, Blanco DR, Lovett MA. Prurification and proteomic analysis of outer membrane vesicles from a clinical isolate of Leptospira interrogans serovar copenhageni. Proteomics. 2005; 5(1): 144-152.

Hsie WJ, Chang YF, Chen CS, Pan MJ. Omp52 is a growth-phase-regulated outer membrane protein of Leptospira santarosai serov ar shermani . FEMS Microbiol Lett. 2005; 243(2):339-345.

Yang CW, Wu MS, Pan MJ, Hsieh WJ, Vandewalle A, Huang CC. The Leptospira outer membrane protein LipL32 induces tubulointerstitial nephritis-mediated gene expression in mouse proximal tubule cells. J. Am. Soc. Nephrol. 2002; 13(8):2037-2045.

Branger C, Sonrier C, Chatrenet B, Klonjkowski B, Ruvoen-Clouet N. Identification of the hemolysis-associated protein 1 as a cross-protective immunogen of Leptospira interrogans by adenovirus-mediated vaccination. Infect Immun. 2001; 69(11):6831-6838.

Haake DA, Martinich C, Summers TA, et al. Characterization of leptospiral outer membrane lipoproptein LipL36: Downregulation associated with late-log-phase growth and mammalian infection. Infect Immun. 1998; 66(4):1579-1587.

Shang ES, Exner MM, Summers TA, et al. The rare outer membrane protein, OmpL1, of pathogenic Leptospira species is a heat-modifiable porin. Infect Immun. 1995; 63(8):3174-3181.

Shang ES, Summers TA, Haake DA. Molecular cloning and sequence analysis of the gene encoding LipL41, a surface-exposed lipoprotein of pathogenic Leptospira. Infect Immun. 1996; 64(6): 2322-2330.

Barnett J, Barnett D, Bolin C, Summers T, Wagar E. Expression and distribution of Leptospira outer membrane components during renal infection of hamsters. Infect Immun. 1999; 67(2):853-861.

Haake DA, Walker EM, Blanco DR, Bolin CA, Miller JN. Changes in the surface of Leptospira interrogans serovar grippotyphosa during in vitro cultivation. Infect Immun. 1991; 59(3):1131-1140.

Haake DA, Mazel MK, McCoy AM, et al. Leptospiral outer membrane proteins OmpL1 and LipL41 exhibit synergistic immunoprotection. Infect Immun. 1999; 67:6572-6582.

Kelson JS, Adler B, Chapman AJ, Faine S. Identification of leptospiral flagellar antigens by gel electrophoresis and immunoblotting. J Med Microbiol. 1988; 26:47-53.

Haake DA, Matsunaga J. Characterization of the leptospiral outer membrane and description of three novel leptospiral membrane proteins. Infect Immun. 2002; 70(9):4936-4945.

Downloads

Published

2011-12-20

How to Cite

1.
Batista N, Arencibia D, Rosario L, Jirón W, Duttman C. Cell antigenic profile of Leptospira strains isolated in Leon and Chinandega, Nicaragua. Ars Pharm [Internet]. 2011 Dec. 20 [cited 2024 Nov. 27];52(4):12-7. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/4757

Issue

Vol. 52 No. 4 (2011)

Section

Original Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).